Shanghai Chest Hospital

HUTCHMED's ORPATHYS and TAGRISSO Combination Receives Priority Review in China for Lung Cancer

5 months ago

• HUTCHMED's NDA for ORPATHYS and TAGRISSO combination gains priority review in China for EGFR mutation-positive NSCLC with MET amplification. • The NDA is supported by Phase III SACHI trial data, which met its primary endpoint of progression-free survival. • The NMPA previously granted Breakthrough Therapy designation to the combination in December 2024, potentially expediting its market entry. • Acceptance of the NDA triggers a milestone payment from AstraZeneca to HUTCHMED, strengthening their collaboration.

Incyte's Retifanlimab Shows Positive Phase 3 Results in Non-Small Cell Lung Cancer

6 months ago

• Incyte's Phase 3 POD1UM-304 trial showed retifanlimab plus chemotherapy significantly improved overall survival in NSCLC patients. • The combination therapy resulted in a median overall survival of 18.1 months compared to 13.4 months with chemotherapy alone. • The study also met secondary endpoints, including progression-free survival, overall response rate, and duration of response. • Incyte plans to submit a supplemental Biologics License Application to the FDA in 2025.

Shanghai Chest Hospital to Initiate CAR-T Therapy Trial for Lung Cancer

7 months ago

• Shanghai Chest Hospital will begin a clinical trial in January to assess a novel CAR-T cell therapy for lung cancer, aiming to enroll 20 patients in the first phase. • The trial leverages CAR-T, an immunotherapy that reprograms a patient's immune cells to target and combat their specific cancer. • Chinese researchers have made significant strides in lung cancer treatment, achieving parity with developed countries in providing advanced therapies to patients. • Dr. Lu Shun's work on EGFR-mutated lung cancer has established a globally recognized "China Plan" for precise and innovative treatment.

Sorrento's License Partner, Lee's Pharm, Announces Full Enrollment in Phase III Trial of Socazolimab for ES-SCLC

3 years ago

Lee's Pharmaceutical Holdings Limited, a subsidiary of Sorrento Therapeutics, has completed the enrollment of 498 patients for a Phase III clinical trial of Socazolimab, an anti-PD-L1 monoclonal antibody, combined with chemotherapy for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). The trial, involving 54 centers across China, is led by Prof. Shun Lu from Shanghai Chest Hospital, with an interim analysis expected in April 2023.